Design and Crystal Structures of Protein Kinase B-Selective Inhibitors in Complex with Protein Kinase a and Mutants

Journal of Medicinal Chemistry

Volumn 48, Issue 1, 2005, Pages 163-170

  Breitenlechner, Christine B ^a   Friebe, Walter Gunar ^b   Brunet, Emmanuel ^b   Werner, Guido ^b   Graul, Klaus ^b   Thomas, Ulrike ^b   Künkele, Klaus Peter ^b   Schäfer, Wolfgang ^b   Gassel, Michael ^c   Bossemeyer, Dirk ^c   Huber, Robert ^a   Engh, Richard A ^a,b   Masjost, Birgit ^b  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; N [4 [4 (2 HYDROXY 5 PIPERIDIN 1 YLBENZOYL)BENZOYLAMINO]AZEPAN 3 YL]ISONICOTINAMIDE; N [4 [4 (5 DIMETHYLAMINO 2 HYDROXYBENZOYL)BENZOYLAMINO]AZEPAN 3 YL]ISONICOTINAMIDE; N [4 [4 [3 (3,3 DIMETHYLPIPERIDIN 2 YL) 2 FLUORO 6 HYDROXYBENZOYL]BENZOYLAMINO]AZEPAN 3 YL]ISONICOTINAMIDE; N [4 [4 [5 (3,3 DIMETHYLPIPERIDIN 1 YLBENZOYL)BENZOYLAMINO]AZEPAN 3 YL]ISONICOTINAMIDE; N [4 [4 [5 (4,4 DIMETHYLPIPERIDIN 1 YL) 2 HYDROXYBENZOYL]BENZOYLAMINO]AZEPAN 3 YL]ISONICOTINAMIDE; PROTEIN KINASE B INHIBITOR; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG BINDING; DRUG BINDING SITE; DRUG DESIGN; DRUG INHIBITION; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; SEQUENCE HOMOLOGY;

ADENOSINE TRIPHOSPHATE; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ENZYME INHIBITORS; MODELS, MOLECULAR; MUTATION; PROTEIN CONFORMATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; REPRODUCIBILITY OF RESULTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 19944426184     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049701n     Document Type: Article

References (42)

1. Cohen, P. Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Discovery 2002, 1, 309-315.
2. Vanhaesebroeck, B.; Alessi, D. R. The PI3K-PDK1 connection: more than just a road to PKB. Biochem. J. 2000, 346 Pt 3, 561-576.
3. Alessi, D. R.; Cohen, P. Mechanism of activation and function of protein kinase B. Curr. Opin. Genet. Dev. 1998, 8, 55-62.
4. Blume-Jensen, P.; Hunter, T. Oncogenic kinase signaling. Nature 2001, 411, 355-365.
5. Datta, S. R.; Brunet, A.; Greenberg, M. E. Cellular survival: a play in three Akts. Genes Dev. 1999, 13, 2905-2927.
6. Kandel, E. S.; Hay, N. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp. Cell Res. 1999, 253, 210-229.
7. Testa, J. R.; Bellacosa, A. AKT plays a central role in tumorigenesis. Proc. Natl. Acad. Sci. U.SA. 2001, 98, 10983-10985.
8. Vivanco, I.; Sawyers, C. L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2, 489-501.
9. Thakkar, H.; Chen, X.; Tyan, F.; Gim, S.; Robinson, H.; Lee, C.; Pandey, S. K.; Nwokorie, C.; Onwudiwe, N.; Srivastava, R. K. Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance. J. Biol. Chem. 2001, 276, 38361-38369.
10. Malik, S. N.; Brattain, M.; Ghosh, P. M.; Troyer, D. A.; Prihoda, T.; Bedolla, R.; Kreisberg, J. I. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin. Cancer Res. 2002, 8, 1168-1171.
11. Stal, O.; Perez-Tenorio, G.; Akerberg, L.; Olsson, B.; Nordenskjold, B.; Skoog, L.; Rutqvist, L. E. Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res. 2003, 5, R37-44.
12. Knighton, D. R.; Zheng, J. H.; Teneyck, L. F.; Ashford, V. A.; Xuong, N. H.; Taylor, S. S.; Sowadski, J. M. Crystal-structure of the catalytic subunit of cyclic adenosine-monophosphate dependent protein-kinase. Science 1991, 253, 407-414.
13. Breitenlechner, C. B.; Wegge, T.; Berillon, L.; Graul, K.; Marzenell, K.; Friebe, W.-G.; Thomas, U.; Schumacher, R.; Huber, R.; Engh, R. A.; Masjost, B. Structure-based optimization of novel azepane derivatives as PKB inhibitors. J. Med. Chem. 2004, 47, 1375-1390.
14. Gassel, M.; Breitenlechner, C. B.; Konig, N.; Huber, R.; Engh, R. A.; Bossemeyer, D. The protein kinase C inhibitor bisindolyl maleimide 2 binds with reversed orientations to different conformations of protein kinase A. J. Biol. Chem. 2004, 279, 23679-23690.
15. Breitenlechner, C.; Gassel, M.; Hidaka, H.; Kinzel, V.; Huber, R.; Engh, R. A.; Bossemeyer, D. Protein kinase A in complex with rho-kinase inhibitors Y-27632, fasudil, and H-1152P: Structural basis of selectivity. Structure 2003, 11, 1595-1607.
16. Prade, L.; Engh, R. A.; Girod, A.; Kinzel, V.; Huber, R.; Bossemeyer, D. Staurosporine-induced conformational changes of cAMP-dependent protein kinase catalytic subunit explain inhibitory potential. Structure 1997, 5, 1627-1637.
17. Engh, R. A.; Girod, A.; Kinzel, V.; Huber, R.; Bossemeyer, D. Crystal structures of catalytic subunit of cAMP-dependent protein kinase in complex with isoquinolinesulfonyl protein kinase inhibitors H7, H8, and H89 - Structural implications for selectivity. J. Biol. Chem. 1996, 271, 26157-26164.
18. Narayana, N.; Diller, T. C.; Koide, K.; Bunnage, M. E.; Nicolaou, K. C.; Brunton, L. L.; Xuong, N. H.; Ten Eyck, L. F.; Taylor, S. S. Crystal structure of the potent natural product inhibitor balanol in complex with the catalytic subunit of cAMP-dependent protein kinase. Biochemistry 1999, 38, 2367-2376.
19. Akamine, P.; Madhusudan; Brunton, L. L.; Ou, H. D.; Canaves, J. M.; Xuong, N.-h.; Taylor, S. S. Balanol analogues probe specificity determinants and the conformational malleability of the cyclic 3′,5′-adenosine monophosphate-dependent protein kinase catalytic subunit. Biochemistry 2004, 43, 85-96.
20. Johnson, D. A.; Akamine, P.; Radzio-Andzelm, E.; Madhusudan; Taylor, S. S. Dynamics of cAMP-dependent protein kinase. Chem. Rev. 2001, 101, 2243-2270.
21. Engh, R. A.; Bossemeyer, D. The protein kinase activity modulation sites: Mechanisms for cellular regulation - Targets for therapeutic intervention. Adv. Enzyme Regul. 2001, 41, 121-149.
22. Breitenlechner, C.; Engh, R. A.; Huber, R.; Kinzel, V.; Bossemeyer, D.; Gassel, M. The typically disordered N-terminus of PKA can fold as a helix and project the myristoylation site into solution. Biochemistry 2004, 43, 7743-7749.
23. Gassel, M.; Breitenlechner, C. B.; Ruger, P.; Jucknischke, U.; Schneider, T.; Huber, R.; Bossemeyer, D.; Engh, R. A. Mutants of protein kinase a that mimic the ATP-binding site of protein kinase B (AKT). J. Mol. Biol. 2003, 329, 1021-1034.
24. Yang, J.; Cron, P.; Good, V. M.; Thompson, V.; Hemmings, B. A.; Barford, D. Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat. Struct. Biol. 2002, 9, 940-944.
25. Yang, J.; Cron, P.; Thompson, V.; Good, V. M.; Hess, D.; Hemmings, B. A.; Barford, D. Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Mol. Cell 2002, 9, 1227-1240.
26. Huang, X.; Begley, M.; Morgenstern, K. A.; Gu, Y.; Rose, P.; Zhao, H. L.; Zhu, X. T. Crystal structure of an inactive Akt2 kinase domain. Structure 2003, 11, 21-30.
27. Masjost, B.; Schumacher, R.; Friebe, W.-G. Novel azepane derivatives. PCT Int. Appl. (Roche Diagnostics GmbH, Germany): W003/076429, 2003.
28. Barbier, P.; Huber, I.; Schneider, F.; Stadlwieser, J.; Taylor, S. Preparation of 3-amino/hydroxy-4-[4-benzoylphenylcarboxylamino/ oxyjazepine and homologue protein kinase inhibitors. Eur. Pat. Appl. (F. Hoffmann-La Roche AG, Switz.). EP663393, 1995; 47 pp.
29. Barbier, P.; Stadlwieser, J.; Taylor, S. Novel azepanes and their ring homologues for therapy and prophylaxis of protein kinase mediated diseases. PCT Int. Appl. (F. Hoffmann-La Roche Ag, Switz.). WO9702249, 1997; 43 pp.
30. Jaeger, D. A.; Finley, C. T.; Walter, M. R.; Martin, C. A. Preparation and characterization of base-sensitive destructible surfactants. J. Org. Chem. 1986, 51, 3956-3959.
31. Ranu, B. C.; Ghosh, K.; Jana, U. Simple and Improved Procedure for Regioselective Acylation of Aromatic Ethers with Carboxylic Acids on the Solid Surface of Alumina in the Presence of Trifluoroacetic Anhydride. J. Org. Chem. 1996, 61, 9546-9547.
32. McKinney, L. L.; Uhing, E. H.; Setzkorn, E. A.; Cowan, J. C. Cyanoethylation of a-amino acids. I. Monocyanoethyl derivatives. J. Am. Chem. Soc. 1950, 72, 2599-2603.
33. Albertson, N. F. Piperidine and azabicyclo compounds. I. Via Michael condensations. J. Am. Chem. Soc. 1950, 72, 2594-2599.
34. Periasamy, M.; Jayakumar, K. N.; Bharathi, P. Aryltitanium Species through the Reaction of N,N-Dialkylarylamines with TiCl4: Oxidative Coupling, N-Dealkylation, and Reaction with Electrophiles. J. Org. Chem. 2000, 65, 3548-3550.
35. Berardi, F.; Ferorelli, S.; Colabufo, N. A.; Leopoldo, M.; Perrone, R.; Tortorella, V. A multireceptorial binding reinvestigation on an extended class of s ligands: N-[w-(indan-1-yl and tetralin-1-yl)alkyl] derivatives of 3,3-dimethylpiperidine reveal high affinities towards si and EBP sites. Bioorg. Med. Chem. 2001, 9, 1325-1335.
36. Olsen, S. R.; Uhler, M. D. Affinity purification of the C-alpha and C-beta isoforms of the catalytic subunit of cAMP-dependent protein-kinase. J. Biol. Chem. 1989, 264, 18662-18666.
37. Bailey, S. The CCP4 suite - programs for protein crystallography. Acta Crystallogr. Sect. D: Biol. Crystallogr. 1994, 50, 760-763.
38. Potterton, E.; Briggs, P.; Turkenburg, M.; Dodson, E. A graphical user interface to the CCP4 program suite. Acta Crystallogr. Sect. D: Biol. Crystallogr. 2003, 59, 1131-1137.
39. Gerber, P. R.; Muller, K. MAB, a generally applicable molecular-force field for structure modeling in medicinal chemistry. J. Comput.-Aided Mol. Des. 1995, 9, 251-268.
40. Kraulis, P. J. MOLSCRIPT - a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 1991, 24, 946-950.
41. Esnouf, R. M. Further additions to MolScript version 1.4, including reading and contouring of electron-density maps. Acta Crystallogr. Sect. D: Biol. Crystallogr. 1999, 55, 938-940.
42. Merritt, E. A.; Bacon, D. J. Raster3D: Photorealistic molecular graphics. Macromol. Crystallogr. B 1997; pp 505-524.